Regeneron Pharmaceuticals (REGN) Capital Leases (2009 - 2025)

Regeneron Pharmaceuticals' Capital Leases history runs 16 years deep, the most recent figure standing at $720.0 million for Q4 2025.

• In Q4 2025, Capital Leases changed 0.0% year-over-year to $720.0 million; the TTM figure through Dec 2025 stood at $720.0 million (changed 0.0% YoY), while the FY2025 annual figure was $720.0 million, changed 0.0% from the prior year.
• Capital Leases was $720.0 million for Q4 2025 at Regeneron Pharmaceuticals, roughly flat from $720.0 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $720.0 million in Q1 2022 to a low of $720.0 million in Q1 2022.
• Historically, Capital Leases has averaged $720.0 million across 4 years, with a median of $720.0 million in 2022.
• Biggest YoY gain for Capital Leases was 0.0% in 2023; the steepest drop was 0.0% in 2023.
• A 4-year view of Capital Leases shows it stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
• The last three Capital Leases figures came in at $720.0 million (Q4 2025), $720.0 million (Q3 2025), and $720.0 million (Q2 2025), per Business Quant data.